JG
BIO icon

Jefferies Group’s Bio-Rad Laboratories Class A BIO Stock Holding History

Jefferies Group’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-417
Closed -$206K – 1660
2022
Q2 		$206K Sell
417
-2,038
-83% -$1.06M ﹤0.01% 1270
2022
Q1 		$1.38M Buy
+2,455
New +$1.48M 0.01% 804
2020
Q4 		– Sell
-400
Closed -$206K – 1565
2020
Q3 		$206K Sell
400
-3,300
-89% -$1.67M ﹤0.01% 1180
2020
Q2 		$1.67K Buy
+3,700
New +$1.63M 0.02% 620
2020
Q1 		– Sell
-3,630
Closed -$1.34M – 2077
2019
Q4 		$1.34M Sell
3,630
-6,670
-65% -$2.35M 0.01% 1284
2019
Q3 		$3.43M Buy
10,300
+7,800
+312% +$2.54M 0.03% 731
2019
Q2 		$781K Sell
2,500
-10,822
-81% -$3.24M 0.01% 1426
2019
Q1 		$4.07M Buy
13,322
+9,769
+275% +$2.64M 0.03% 529
2018
Q4 		$825K Buy
3,553
+1,295
+57% +$347K 0.01% 1251
2018
Q3 		$707K Buy
2,258
+80
+4% +$24.8K ﹤0.01% 1488
2018
Q2 		$628K Buy
2,178
+1,164
+115% +$321K ﹤0.01% 1481
2018
Q1 		$254K Sell
1,014
-9,766
-91% -$2.49M ﹤0.01% 1869
2017
Q4 		$2.57M Buy
10,780
+7,869
+270% +$1.91M 0.01% 860
2017
Q3 		$647K Sell
2,911
-6,973
-71% -$1.57M ﹤0.01% 1506
2017
Q2 		$2.24M Buy
9,884
+1,807
+22% +$394K 0.01% 889
2017
Q1 		$1.61M Buy
8,077
+2,911
+56% +$561K 0.01% 1032
2016
Q4 		$942K Buy
5,166
+668
+15% +$114K 0.01% 1310
2016
Q3 		$737K Buy
4,498
+2,425
+117% +$368K ﹤0.01% 1436
2016
Q2 		$296K Sell
2,073
-11,386
-85% -$1.62M ﹤0.01% 1658
2016
Q1 		$1.84M Buy
13,459
+9,851
+273% +$1.29M 0.01% 880
2015
Q4 		$500K Sell
3,608
-4,658
-56% -$646K ﹤0.01% 1539
2015
Q3 		$1.11M Buy
8,266
+2,631
+47% +$379K 0.01% 1163
2015
Q2 		$849K Buy
5,635
+3,016
+115% +$431K ﹤0.01% 1312
2015
Q1 		$354K Buy
+2,619
New +$325K ﹤0.01% 1527
2014
Q3 		– Sell
-2,223
Closed -$266K – 2138
2014
Q2 		$266K Buy
+2,223
New +$271K ﹤0.01% 1598

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Jefferies Group's BIO Position: Q3 2022 in Review

Jefferies Group sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2022, closing a stake of 417 shares — an estimated $206K sold.

Jefferies Group first reported a position in BIO in Q2 2014 and held it in 25 quarters. The position peaked at $4.07M in Q1 2019. 485 funds tracked by Wall St. Rank hold BIO as of Q3 2022.

  • Jefferies Group reported no remaining Bio-Rad Laboratories Class A position as of Q3 2022 after selling out during the quarter.
  • Jefferies Group sold 417 Bio-Rad Laboratories Class A shares in Q3 2022, an estimated $206K.
  • Jefferies Group first reported a position in Bio-Rad Laboratories Class A in Q2 2014 and held it in 25 quarters.
  • Jefferies Group's Bio-Rad Laboratories Class A position peaked at $4.07M in Q1 2019.
  • 485 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.